Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease (NPAD)

Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03173846

Acronym

NPAD

Enrollment

Registered

2017-06-02

Start date

2017-05-05

Completion date

2019-12-31

Last updated

2020-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

neurofeedback, episodic memory, real-time functional MRI

Brief summary

This study aims to predict cognitive decline using a performance endophenotype of neuro-feedback based on functional magnetic resonance imaging in real time in a population at risk for Alzheimer's disease (AD).

Detailed description

In this research project, a longitudinal study in a healthy population that is under increased risk of developing AD will be performed. It is anticipated that some of the participating subjects will develop episodic memory decline within this longitudinal follow-up. The memory binding Test (MBT) and/or the Free and Cued Selective Reminding Test (FCSRT), the most accurate and reliable available episodic memory tests, are going to be performed by the subjects at multiple longitudinal data collection points. The project proposes to develop a real-time functional magnetic resonance imaging (rtfMRI) task, and to test whether the subjects' performance on the task can predict the apparition of cognitive decline. The impact of other relevant biomarkers by adding them to the model: age, gender, number of APOE-e4 alleles, cognitive scores, cerebrospinal fluid (CSF) biomarkers, amyloid Positron Emission Tomography (PET), lifestyle habits and clinical background will be studied.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to 79 Years

Inclusion criteria

* Adult men and women (aged 45-75) that have participated in the study 45-65/FPM2012. * Persons that accept the study's test and procedures that are as follows: magnetic resonance imaging and neuropsychological tests. * Signature of the study's informed consent form, accepting to not receive information with regards to any research results that are not clinically relevant.

Exclusion criteria

* Any contraindication to MRI (e.g. pacemaker, claustrophobia, etc.) * Any condition that according to the investigator's judgement could interfere with the proper execution of the study's procedures and/or its follow-up.

Design outcomes

Primary

Measure	Time frame	Description
Change in cognition	12 months	Predictive value of neurofeedback performance

Countries

Spain

Outcome results